Influence of method of preparation on solubility, physicochemical properties and in-vitro release profile of simvastatin- cyclodextrin inclusion complexes: A comparative study

International Journal of ChemTech Research

Volumn 2, Issue 1, 2010, Pages 562-571

  Shiralashetti, Shivanand ^a   Patil, Ajaykumar ^a   Patil, Jagadevappa ^b  

^a KARNATAKA COLLEGE OF PHARMACY   (India)

^b BLDE UNIVERSITY   (India)

Author keywords

CD; Dissolution rate; HP CD; Inclusion complex; Simvastatin; Spray drying

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; SIMVASTATIN;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISSOLUTION; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; IN VITRO STUDY; INTERMETHOD COMPARISON; SPRAY DRYING; SURFACE PROPERTY;

EID: 77953435386     PISSN: None     EISSN: 09744290     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Company literature on ZOCOR-(Simvastatin) Tablets. Merck and Co., Inc, NJ, USA, pp.1-2, 6.
2. Cheng H, Sutton SC, Pipikin JD, Zentner GM, Rogers JD, Schwartz I, Mitchel Y B, Grasing K, Schwartz M S, Amin R D, Lui L, Ebel D L, Coulter A, Engle A, McClelland G A, Lui C A, Pork G S. Evaluation of sustained/controlled- release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor in dogs and humans, Pharm. Res. 10 (1993) 1683-1687.
3. McClelland C A, Stubbs R J, Fix J A, Pogany S A, Zentner G M. Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form, Pharm. Res. 8 (1991) 873-876.
4. Ambike A A, Mahadik K R, Paradkar A. Spray-dried amorphous solid dispersions of simvastatin a low Tg drug: In Vitro and in Vivo evaluations, Pharm. Res. 22 (2005) 990-998.
5. Kang B K, Lee J S, Chon S K, Jeong S Y, Yuk S H, Khang G, Lee H B, Cho S H. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs, Int. J. Pharm. 274 (2004) 65-73.
6. Loftsson T Brewster M. Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization, J. Pharm. Sci. 85 (1996) 1017-1025.
7. Peters J, Neeskens P, Tollenaere J P, Van P, Remoortere, Brewster M E. Characterization of the interaction of 2-hydroxypropylbeta- cyclodextrin with itraconazole at pH 2, 4, and 7, J. Pharm. Sci. 91 (2002) 1414-1422.
8. Al-Marzouqi A H, Shehatta L, Jobe B, Dowaider A. Phase solubility and inclusion complex of itraconazole with betacyclodextrin using supercritical carbon dioxide, J. Pharm. Sci. 95 (2006) 292-304.
9. Wen X, Liu Z, Zhu T. Mass spectrometry and molecular modeling studies on the inclusion complexes between a,bcyclodextrins and simvastatin, Chem. Phys. Lett. 405 (2005) 114-117.
10. Tirucherai G S, Mitra A K. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir, AAPS Pharm. Sci. Tech. 4 (2003) E45.
11. Higuchi T and Connors KA. Phasesolubility techniques. Adva Anal Chem Instr. 1965; 4: 217-22.
12. Veiga F, Teixeira-Dias J J C, Kedzierewicz F, Sousa A, Maincent P. Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. International Journal of Pharmaceutics. 1996; 129; 63-71.
13. Seoung W J, Min S K, Jeong S K, Hee J P, Sibeum L, Jong SW, Sung JH. Preparation and characterization of Simvastatin /hydroxypropyl-β- cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eropean Journal of Pharmaceutics and Biopharmaceutics. 66 (2007) 413-421.
14. Patel RP, Patel MM. Physico-chemical characterization and in vitro dissolution bahaviour of Simvastatin β-cyclodextrin inclusion compounds. http://www.drug deliverytechonline.com/drugdelivery/20070 5/templates/pageviewer